Dr James S. Kuo
Jim is a Co-founder, Senior Partner and Chief Investment Officer of Milolst Global Inc. He is responsible for the Firm's investment portfolios. As the Chief Investment Officer, Jim oversees a team of professionals that have responsibilities such as managing and monitoring investment activity, managing buyouts, working with unit managing director's and maintaining good investor relations.
Most recently, he served as Chairman and Chief Executive Officer of Synthetic Biologics, a publicly-traded biotech company. While there, two financings and a collaboration with a European pharmaceutical company were completed. Synthetic’s stock went from $0.82 to $2.30 during his tenure as CEO.
Dr. Kuo has also served as Chairman and Chief Executive Officer of BioMicro Systems. The company received several rounds of venture financing, achieved several million dollars in sales of an internally developed instrument for microarray research, and was eventually sold to a major European pharmaceutical company.
Dr. Kuo has further served as the Chief Executive Officer of Discovery Laboratories, a publicly-traded company developing surfactant-based respiratory therapeutics. Dr. Kuo has been Associate Director of Licensing and Development at Pfizer and Vice President of Business Development at Myriad Genetics.
He has also been Managing Director of HealthCare Ventures, a $378 million venture capital fund. He received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.